Alzamend Neuro Inc Total Assets
Alzamend Neuro Inc total assets. Based on the latest financial reports, Alzamend Neuro Inc (ALZN) holds total assets worth $8.54 Million USD as of July 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALZN company net worth for the company's overall valuation and market capitalisation.
Total Assets of Alzamend Neuro Inc (2016–2026)
Total assets of Alzamend Neuro Inc from 2016 to 2026. This chart illustrates how Alzamend Neuro Inc's total assets have evolved over time, based on quarterly financial data. See Alzamend Neuro Inc stock price for real-time trading data and today's change.
Alzamend Neuro Inc - Asset Composition Analysis
Alzamend Neuro Inc Total Assets Breakdown (April 2026)
Alzamend Neuro Inc total assets breakdown as of April 2026. Alzamend Neuro Inc's total assets of $8.54 Million consist of 84.9% current assets and 15.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2026)
This chart illustrates how Alzamend Neuro Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Alzamend Neuro Inc (ALZN) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alzamend Neuro Inc's current assets represent 84.9% of total assets in 2026, an increase from 18.3% in 2016.
- Cash Position: Cash and equivalents constituted 34.2% of total assets in 2026, up from 3.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Alzamend Neuro Inc Competitors by Total Assets
Key competitors of Alzamend Neuro Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Alzamend Neuro Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.01 | 6.03 | 9.83 |
| Quick Ratio | 3.01 | 6.03 | 9.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.52 Million | $4.95 Million | $13.03 Million |
Alzamend Neuro Inc - Advanced Valuation Insights
This section examines the relationship between Alzamend Neuro Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.19 |
| Latest Market Cap to Assets Ratio | 3.39 |
| Asset Growth Rate (YoY) | -54.8% |
| Total Assets | $2.08 Million |
| Market Capitalization | $7.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Alzamend Neuro Inc's assets at a significant premium (3.39x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Alzamend Neuro Inc's assets decreased by 54.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Alzamend Neuro Inc (2016–2026)
The table below shows the annual total assets of Alzamend Neuro Inc from 2016 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-04-30 | $2.08 Million | -54.83% |
| 2025-04-30 | $4.60 Million | +628.80% |
| 2024-04-30 | $631.59K | -89.32% |
| 2023-04-30 | $5.92 Million | -59.25% |
| 2022-04-30 | $14.52 Million | +398.40% |
| 2021-04-30 | $2.91 Million | +60.56% |
| 2020-04-30 | $1.81 Million | +20.86% |
| 2019-04-30 | $1.50 Million | -37.88% |
| 2018-04-30 | $2.42 Million | +1726.26% |
| 2017-04-30 | $132.29K | +332.13% |
| 2016-04-30 | $30.61K | -- |
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, … Read more